Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.62 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.51 |
| ▸ | HTR3B | O95264 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27415238 | 0.94 | PRKCA (0.59) | PRKCAPRKCQPRKCDHTR3EHTR3B | |
| SCHEMBL30077193 | 0.89 | PRKCA (0.65) | PRKCAPRKCQPRKCDHTR3EHTR3B | |
| SCHEMBL15347217 | 0.89 | PRKCA (0.65) | PRKCAPRKCQPRKCDHTR3EHTR3B | |
| SCHEMBL836939 | 0.86 | GNE (0.60) | PRKCAPRKCQPRKCDALDH1A1HSD11B1 | |
| SCHEMBL14879835 | 0.86 | GNE (0.56) | PRKCAPRKCQPRKCDALDH1A1HSD11B1 | |
| SCHEMBL1781915 | 0.85 | HSD11B1 (0.61) | PRKCAPRKCQPRKCDALDH1A1HSD11B1 | |
| SCHEMBL31432279 | 0.85 | HSD11B1 (0.61) | PRKCAPRKCQPRKCDALDH1A1HSD11B1 | |
| SCHEMBL15347230 | 0.84 | PRKCA (0.57) | PRKCAPRKCQPRKCDHTR3EHTR3B | |
| SCHEMBL30077115 | 0.84 | PRKCA (0.57) | PRKCAPRKCQPRKCDHTR3EHTR3B | |
| SCHEMBL21493103 | 0.82 | PRKCQ (0.62) | PRKCAPRKCQPRKCDHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995091-B2 | CXCR4 receptor antagonists | PROXIMAGEN LLC (US) | 2021-05-04 | — | — | US | disclosed |
| WO-2020222190-A1 | CRYSTALLINE FORM OF 6-[4-[1 -(PROPAN-2-YL)PIPERIDIN-4-YL]-1,4-DIAZEPAN-1 -YL]-N-(PYRDIN-4-YL)PYRIDINE-2-CARBOXAMIDE | PROXIMAGEN, LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020222189-A1 | CRYSTALLINE FORM OF 6-[4-[1-(PROPAN-2-YL)PIPERIDIN-4-YL]-1,4-DIAZEPAN-1-YL]-N-(PYRDIN-4-YL)PYRIDINE-2-CARBOXAMIDE | PROXIMAGEN, LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| US-10155761-B2 | CXCR4 receptor antagonists | PROXIMAGEN, LLC (US) | 2018-12-18 | — | — | US | disclosed |
| EP-2927224-B1 | Receptor antagonists | PROXIMAGEN LTD (GB) | 2018-10-03 | — | — | EP | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-9353086-B2 | CXCR4 receptor antagonists | PROXIMAGEN LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| EP-2927224-A1 | Receptor antagonists | Proximagen Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| EP-2627649-B1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2015-04-08 | — | — | EP | disclosed |
| US-20130289020-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| EP-2627649-A1 | CXCR4 RECEPTOR ANTAGONISTS | Proximagen Limited (GB) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012049277-A1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226106-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | PRKCA 2488/4885PRKCQ 2160/4885PRKCD 1936/4885 |
| US-20130289020-A1 | CXCR4 Receptor Antagonists | CXCR4, ACKR3, CXCR1 | PRKCA 3119/4885PRKCQ 3159/4885PRKCD 2540/4885 |
| US-10155761-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | PRKCA 2488/4885PRKCQ 2160/4885PRKCD 1936/4885 |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | PRKCA 2488/4885PRKCQ 2160/4885PRKCD 1936/4885 |
| US-10995091-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | PRKCA 2488/4885PRKCQ 2160/4885PRKCD 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.